• 1
    Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease (Cochrane Review). In: The Cochrane Database Systematic Reviews. Issue 1, 2006. Chichester ( UK ) : John Wiley and Sons; 2006.
  • 2
    De Deyn PP, Katz IR, Brodaty H, Lyons B, Greenspan A, Burns A. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone. Clin Neurol Neurosurg. 2005;107(6):497508.
  • 3
    Hugenholtz GW, Heerdink ER, Van Staa TP, Nolen WA, Egberts AC. Risk of hip/femur fractures in patients using antipsychotics. Bone. 2005;37(6):86470.
  • 4
    Kolanowski A, Fick D, Waller JL, Ahern F. Outcomes of antipsychotic drug use in community-dwelling elders with dementia. Arch Psychiatr Nurs. 2006;20(5):21725.
  • 5
    Liperoti R, Onder G, Lapane KL, Mor V, Friedman JH, Bernabei R, et al. Conventional or atypical antipsychotics and the risk of femur fracture among elderly patients: results of a case-control study. J Clin Psychiatry. 2007;68(6):92934.
  • 6
    Normand SL, Sykora K, Li P, Mamdani M, Rochon PA, Anderson GM. Readers guide to critical appraisal of cohort studies: 3. Analytical strategies to reduce confounding. BMJ. 2005;330(7498):10213.
  • 7
    Knol W, Van Marum RJ, Jansen PA, Souverein PC, Schobben AF, Egberts AC. Antipsychotic drug use and risk of pneumonia in elderly people. J Am Geriatr Soc. 2008;56(4):6616.
  • 8
    Wada H, Nakajoh K, Satoh-Nakagawa T, Suzuki T, Ohrui T, Arai H, et al. Risk factors of aspiration pneumonia in Alzheimer's disease patients. Gerontology. 2001;47(5):2716.
  • 9
    Department of Health and Ageing. Australian Statistics on Medicines. Canberra ( AUST ) : Commonwealth of Australia; 2006.
  • 10
    Hollis J, Grayson D, Forrester L, Brodaty H, Touyz S, Cumming R. Antipsychotic medication dispensing and risk of death in veterans and war widows 65 years and older. Am J Geriatr Psychiatry. 2007;15(11):93241.
  • 11
    Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005;353(22):233541.
  • 12
    Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ. 2007;176(5):62732.
  • 13
    Rochon PA, Gurwitz JH, Sykora K, Mamdani M, Streiner DL, Garfinkel S, et al. Reader's guide to critical appraisal of cohort studies: 1. Role and design. BMJ. 2005;330(7496):8957.
  • 14
    Brookhart MA, Rassen JA, Wang PS, Dormuth C, Mogun H, Schneeweiss S. Evaluating the validity of an instrumental variable study of neuroleptics: can between-physician differences in prescribing patterns be used to estimate treatment effects? Med Care. 2007;45(10 Supl 2):S11622.
  • 15
    Leader S, Mallick R, Roht L. Using medication history to measure confounding by indication in assessing calcium channel blockers and other antihypertensive therapy. J Hum Hypertens. 2001;15(3):1539.
  • 16
    World Health Organization Collaborating Centre for Drug Statistics Methodology. Anatomical Therapeutic Chemical Code Classification Index with Defined Daily Doses [index on the Internet]. Oslo ( NOR ) : Norwegian Institute of Public Health; 2009 [cited 2010 Mar 12]. Available from:
  • 17
    PBS for Health Professionals. Schedule of Pharmaceutical Benefits [schedule on the Internet]. Canberra ( AUST ) : Commonwealth Department of Health and Ageing; 2010 [cited 2010 Mar 12]. Available from:
  • 18
    National Centre for Classification in Health. The International Statistical Classification of Diseases and Related Health Problems 10th revision Australian Modification (ICD–10–AM). 6th ed. Sydney ( AUST ) : University of Sydney; 2005.
  • 19
    Vitry A, Wong SA, Roughead EE, Ramsay E, Barratt J. Validity of medication-based co-morbidity indices in the Australian elderly population. Aust NZ J Public Health. 2009;33(2):12630.
  • 20
    Stukel TA, Fisher ES, Wennberg DE, Alter DA, Gottlieb DJ, Vermeulen MJ. Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. JAMA. 2007;297(3):27885.
  • 21
    Whitaker HJ, Farrington CP, Spiessens B, Musonda P. Tutorial in biostatistics: the self-controlled case series method. Stat Med. 2006;25(10):176897.
  • 22
    Tsiropoulos I, Andersen M, Hallas J. Adverse events with use of antiepileptic drugs: a prescription and event symmetry analysis. Pharmacoepidemiol Drug Saf. 2009;18(6):48391.
  • 23
    Greenland S. An introduction to instrumental variables for epidemiologists. Int J Epidemiol. 2000;29(6):1102.
  • 24
    Rassen JA, Brookhart MA, Glynn RJ, Mittleman MA, Schneeweiss S. Instrumental variables I: instrumental variables exploit natural variation in nonexperimental data to estimate causal relationships. J Clin Epidemiol. 2009;62(12):122632.
  • 25
    Pratt NL, Roughead EE, Salter A, Ryan, P. Antipsychotics and the risk of death in the elderly: An instrumental variable analysis using two preference based instruments. Pharmacoepidemiol Drug Saf. 2010;19(7):699707.
  • 26
    Gill SS, Bronskill SE, Normand SL, Anderson GM, Sykora K, Lam K, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med. 2007;146(11):77586.
  • 27
    Hollis J, Forrester L, Brodaty H, Touyz S, Cumming R, Grayson D. Risk of death associated with antipsychotic drug dispensing in residential aged care facilities. Aust N Z J Psychiatry. 2007;41(9):7518.
  • 28
    De Deyn PP, Rabheru K, Rasmussen A, Bocksberger JP, Dautzenberg PL, Eriksson S, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology. 1999;53(5):94655.